Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest

Cancer Letters

Volumn 333, Issue 2, 2013, Pages 239-243

  Yellen, Paige ^a,b   Chatterjee, Amrita ^a   Preda, Angela ^a   Foster, David A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Cell cycle; EIF4E; MTOR; TGF

Indexed keywords

CASPASE 3; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; S6 KINASE; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CELL LINE, TUMOR; EUKARYOTIC INITIATION FACTOR-4E; G1 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES; SERUM; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

EUKARYOTA; MAMMALIA;

EID: 84876704953     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.041     Document Type: Article

References (33)

1. Toschi A., Lee E., Xu L., Garcia A., Gadir N., Foster D.A. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol. Cell. Biol. 2009, 29:1411-1420.
2. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
3. Bjornsti M.A., Houghton P.J. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004, 5:519-523.
4. Richter J.D., Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005, 433:477-480.
5. Dowling R.J., Topisirovic I., Alain T., Bidinosti M., Fonseca B.D., Petroulakis E., Wang X., Larsson O., Selvaraj A., Liu Y., Kozma S.C., Thomas G., Sonenberg N. MTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010, 328:1172-1176.
6. Hsieh A.C., Costa M., Zollo O., Davis C., Feldman M.E., Testa J.R., Meyuhas O., Shokat K.M., Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17:249-261.
7. Gadir N., Jackson D.N., Lee E., Foster D.A. Defective TGF-β signaling sensitizes human cancer cells to rapamycin. Oncogene 2008, 27:1055-1062.
8. Yellen P., Saqcena M., Salloum D., Feng J., Preda A., Xu L., Rodrik-Outmezguine V., Foster D.A. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011, 10:3948-3956.
9. Song K., Wang H., Krebs T.L., Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation. EMBO J. 2006, 25:58-69.
10. Gadir N., Lee E., Garcia A., Toschi A., Foster D.A. Suppression of TGF-β signaling by phospholipase D. Cell Cycle 2007, 6:2840-2845.
11. Chen Y., Rodrik V., Foster D.A. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 2005, 24:672-679.
12. Chen Y., Zheng Y., Foster D.A. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003, 22:3937-3942.
13. Perillan P.R., Chen M., Potts E.A., Simard J.M. Transforming growth factor- β 1 regulates Kir2.3 inward rectifier K+ channels via phospholipase C and protein kinase C-δ in reactive astrocytes from adult rat brain. J. Biol. Chem. 2002, 277:1974-1980.
14. Runyan C.E., Schnaper H.W., Poncelet A.C. Smad3 and PKCδ mediate TGF- β 1-induced collagen I expression in human mesangial cells. Am. J. Physiol. Renal. Physiol. 2003, 285:F413-422.
15. Massague J. TGF-β in Cancer. Cell 2008, 134:215-230.
16. Jackson D., Zheng Y., Lyo D., Shen Y., Nakayama K., Nakayama K.I., Humphries M.J., Reyland M.E., Foster D.A. Suppression of cell migration by protein kinase Cδ. Oncogene 2005, 24:3067-3072.
17. Choo A.Y., Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009, 8:567-572.
18. Easton J.B., Houghton P.J. Therapeutic potential of target of rapamycin inhibitors. Exp. Opin. Ther. Targets 2004, 8:551-564.
19. Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., Blenis J. MTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 2004, 24:200-216.
20. Jaffee E.M., Hruban R.H., Canto M., Kern S.E. Focus on pancreas cancer. Cancer Cell 2002, 2:25-28.
21. Popat S., Houlston R.S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur. J. Cancer 2005, 41:2060-2070.
22. Harada H., Andersen J.S., Mann M., Terada N., Korsmeyer S.J. P70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. USA 2001, 98:9666-9670.
23. Djouder N., Metzler S.C., Schmidt A., Wirbelauer C., Gstaiger M., Aebersold R., Hess D., Krek W. S6K1-mediated disassembly of mitochondrial URI/PP1 complexes activates a negative feedback program that counters S6K1 survival signaling. Mol. Cell 2007, 28:28-40.
24. Gonzalez-Rodriguez A., Alba J., Zimmerman V., Kozma S.C., Valverde A.M. S6K1 deficiency protects against apoptosis in hepatocytes. Hepatology 2009, 50:216-229.
25. Land H., Parada L.F., Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983, 304:596-602.
26. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
27. Gingras A.C., Raught B., Gygi S.P., Niedzwiecka A., Miron M., Burley S.K., Polakiewicz R.D., Wyslouch-Cieszynska A., Aebersold R., Sonenberg N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001, 15:2852-2864.
28. Cloughesy T.F., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., Liau L., Martin N., Becker D., Bergsneider M., Lai A., Green R., Oglesby T., Koleto M., Trent J., Horvath S., Mischel P.S., Mellinghoff I.K., Sawyers C.L. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5:e8.
29. Tabernero J., Rojo F., Calvo E., Burris H., Judson I., Hazell K., Martinelli E., Ramon y Cajal S., Jones S., Vidal L., Shand N., Macarulla T., Ramos F.J., Dimitrijevic S., Zoellner U., Tang P., Stumm M., Lane H.A., Lebwohl D., Baselga J. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26:1603-1610.
30. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65:7052-7058.
31. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
32. Zhang Y.J., Duan Y., Zheng X.F. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov. Today 2011, 16:325-331.
33. Roulin D., Waselle L., Dormond-Meuwly A., Dufour M., Demartines N., Dormond O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol. Cancer 2011, 10:90.